Skip to content
New: 30 more Indian companies explained, from Ather and Pine Labs to IDBI Bank

Compare · Healthcare

Sun Pharma vs Torrent Pharma: how their businesses differ

The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

How they differ

In FY26, Sun Pharma's revenue of ₹58,462 cr was about 4.2 times Torrent Pharma's ₹13,980 cr (Cityfort calculation: one divided by the other).

Sun Pharma's largest segment is India, 33.8% of revenue in FY26; Torrent Pharma's largest segment is India, 54.7% of revenue in FY26.

Sun Pharma's largest payer group is Buyers in India, 33.8% of revenue (FY26); Torrent Pharma's largest payer group is Customers in India, 58.4% of revenue (FY26).

Neither page lists the other among its competitors.

Sources: Sun Pharma S1, S27, S18 · Torrent Pharma S12, S1, S47, S2, S38, S8

Each company in 5 points

Sun Pharma

  1. 1 · What it sells

    Sun Pharma makes branded medicines for India, generic medicines for the US and other countries, and patented drugs such as Ilumya, and its FY26 revenue from operations was ₹58,462 crore.

    Sources and detail on the Sun Pharma page
  2. 2 · Who pays it

    In FY26, buyers in India paid 33.8% of Sun Pharma's sales, buyers in the US 30.3%, emerging markets 20.1% and the rest of the world 15.8%.

    Sources and detail on the Sun Pharma page
  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, Sun Pharma kept ₹19.0 as profit after ₹2.2 of one-off charges, and in Q2 FY27 a ₹1,269 crore one-off charge cut profit to ₹1,989 crore while profit before one-off items and tax rose 6.3% to ₹4,428 crore.

    Sources and detail on the Sun Pharma page
  4. 4 · Where the operating profit comes from

    Sun Pharma does not report profit by region or product, so the source of its FY26 EBITDA of ₹16,424 crore is not disclosed; patented innovative medicines were 20.7% of its sales, excluding a milestone payment.

    Sources and detail on the Sun Pharma page
  5. 5 · The one thing to watch

    Sun Pharma agreed on 27 Apr 2026 to buy Organon, a company with US$6.2 billion of 2025 revenue, for an enterprise value of US$11.75 billion, and management said on 30 Oct 2026 it expects completion in Q4 FY27.

    Sources and detail on the Sun Pharma page

Torrent Pharma

  1. 1 · What it sells

    Torrent Pharma sells branded medicines in India and Brazil and generic medicines in the US and Germany, and its FY26 revenue from operations was ₹13,980 crore.

    Sources and detail on the Torrent Pharma page
  2. 2 · Who pays it

    In FY26, customers in India paid 58.4% of Torrent's revenue, the US 9.7%, Brazil 9.7%, Germany and Malta 8.9% and other countries 13.2%.

    Sources and detail on the Torrent Pharma page
  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, Torrent kept ₹15.6 as profit, after ₹89 crore of one-off costs (mostly for the JB deal) and a ₹94 crore net loss in other income, while its EBITDA, which leaves out other income, was 32.0% of revenue (Cityfort calculation).

    Sources and detail on the Torrent Pharma page
  4. 4 · Where the operating profit comes from

    Torrent reports a single segment, so it does not say which market earns its FY26 EBITDA of ₹4,470 crore (Cityfort calculation), but for Q1 FY27 it gave operating EBITDA of ₹1,240 crore for its base business and ₹424 crore for JB.

    Sources and detail on the Torrent Pharma page
  5. 5 · The one thing to watch

    Torrent's borrowings were ₹13,874 crore on 30 Sep 2026, up from ₹3,026 crore on 31 Mar 2025, and its interest cost was ₹300 crore in Q2 FY27 against ₹48 crore in Q2 FY26.

    Sources and detail on the Torrent Pharma page

Where each ₹100 went

Each company's own receipt for its latest full financial year, with matching lines in the same order where both have them.

Sun Pharma

Where ₹100 went · FY26

Where ₹100 of Sun Pharma's money went in FY26
Materials and goods bought₹19.1
Employee costs₹18.9
Other running costs (research, marketing, freight)₹29.4
Depreciation, interest and small items₹5.5
One-off charges₹2.2
Income tax₹5.9
Kept as profit for shareholders₹19.0
Total₹100

Of every ₹100 that came in during FY26 (revenue of ₹58,462 crore plus ₹1,972 crore of other income), Sun Pharma kept ₹19.0 as profit for shareholders, after ₹2.2 of one-off charges.

Torrent Pharma

Where ₹100 went · FY26

Where ₹100 of Torrent Pharma's money went in FY26
Materials and goods bought₹24.4
Employee costs₹19.2
Other running costs₹24.2
Depreciation, amortisation and interest₹10.8
One-off costs (mostly JB deal costs)₹0.6
Income tax₹5.3
Kept as profit for shareholders₹15.6
Total₹100

Cityfort calculation from the FY26 results: each line ÷ total money in × 100. Money in = revenue of ₹13,980 crore minus the ₹94 crore net loss in other income = ₹13,886 crore. Profit is the shareholders' share: ₹25 crore more than money in minus the costs shown, because JB's minority shareholders took ₹25 crore of losses before the merger.

Line items differ because each company groups its costs its own way in its filings. Only on Sun Pharma's receipt: Other running costs (research, marketing, freight); Depreciation, interest and small items; One-off charges. Only on Torrent Pharma's receipt: Other running costs; Depreciation, amortisation and interest; One-off costs (mostly JB deal costs).

Sources: Sun Pharma S1 · Torrent Pharma S12, S1

Revenue, net profit and free cash flow

Up to five financial years for each company, drawn on one shared scale per measure. Amounts in ₹ crore as each company reports them.

Revenue

Sun Pharma

Torrent Pharma

Both charts use the same scale. Indian financial years (April to March).
See the numbers
Revenue of Sun Pharma and Torrent Pharma by financial year, ₹ crore
Sun Pharma yearSun Pharma revenueTorrent Pharma yearTorrent Pharma revenue
FY22₹38,655 crFY22₹8,508 cr
FY23₹43,886 crFY23₹9,620 cr
FY24₹48,497 crFY24₹10,728 cr
FY25₹52,578 crFY25₹11,516 cr
FY26₹58,462 crFY26₹13,980 cr

Net profit

Sun Pharma

Torrent Pharma

Both charts use the same scale. Indian financial years (April to March).
See the numbers
Net profit of Sun Pharma and Torrent Pharma by financial year, ₹ crore
Sun Pharma yearSun Pharma net profitTorrent Pharma yearTorrent Pharma net profit
FY22₹3,273 crFY22₹777 cr
FY23₹8,474 crFY23₹1,245 cr
FY24₹9,576 crFY24₹1,656 cr
FY25₹10,929 crFY25₹1,911 cr
FY26₹11,479 crFY26₹2,163 cr

Free cash flow

Sun Pharma

Torrent Pharma

Both charts use the same scale. Indian financial years (April to March); free cash flow = cash from operations minus capital spending, as on each company's page.
See the numbers
Free cash flow of Sun Pharma and Torrent Pharma by financial year, ₹ crore
Sun Pharma yearSun Pharma free cash flowTorrent Pharma yearTorrent Pharma free cash flow
FY22₹7,490 crFY22₹1,600 cr
FY23₹2,874 crFY23₹1,794 cr
FY24₹9,933 crFY24₹2,833 cr
FY25₹11,944 crFY25₹1,974 cr
FY26₹8,810 crFY26₹2,346 cr

Sources: Sun Pharma S7, S6, S5, S1 · Torrent Pharma S24, S5, S4, S23, S22, S3, S20, S2, S12, S1

Growth and net margin, FY22 to FY26

Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net profit as a share of revenue, as on each page.

Sun Pharma

Revenue, per year
+10.9%
Net profit, per year
+36.8%

Torrent Pharma

Revenue, per year
+13.2%
Net profit, per year
+29.2%

Cityfort calculation: compound growth per year from FY22 to FY26 (4 years), from each page's yearly numbers, as reported.

Net margin by year
Net margin (net profit as a share of revenue) of Sun Pharma and Torrent Pharma by financial year, as on each page
YearSun PharmaTorrent Pharma
FY228.5%9.1%
FY2319.3%12.9%
FY2419.7%15.4%
FY2520.8%16.6%
FY2619.6%15.5%

Sources: Sun Pharma S7, S6, S5, S1 · Torrent Pharma S24, S5, S4, S23, S22, S3, S20, S2, S12, S1

Latest quarter, against the same quarter a year earlier

Each page's latest quarter as reported; the change is a Cityfort calculation.

Sun Pharma

Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26

Sun Pharma, Q2 FY27 against Q2 FY26
MeasureQ2 FY27Q2 FY26Change
Revenue₹16,199 cr₹14,478 cr+11.9%
Net profit₹1,989 cr₹3,118 cr−36.2%

Torrent Pharma

Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26

Torrent Pharma, Q2 FY27 against Q2 FY26
MeasureQ2 FY27Q2 FY26Change
Revenue₹4,979 cr₹3,302 cr+50.8%
Net profit₹534 cr₹591 cr−9.6%

Sources: Sun Pharma S9, S20, S17, S13 · Torrent Pharma S17, S14, S12, S10, S7, S6

Who pays each company

Sun Pharma

  • Buyers in India · 33.8% of revenueMedicines sold in India, mostly under Sun Pharma's brands. Its sales team of over 16,000 people visits doctors. Share is of FY26 sales; drug-ingredient sales are counted in the region where they were sold.
  • Buyers in the US · 30.3% of revenueGeneric and innovative medicines sold in the US. US formulation sales were US$1,904 million in FY26.
  • Buyers in emerging markets · 20.1% of revenueMedicines sold in emerging markets. Formulation sales there were US$1,265 million in FY26, up 13%.
  • Buyers in the rest of the world · 15.8% of revenueMedicines sold in other countries. Formulation sales there were US$969 million in FY26, up 14%.

Torrent Pharma

  • Customers in India · 58.4% of revenueWholesale distributors, stockists, pharmacies, online sellers and institutions such as hospitals, which sell to patients on doctors' prescriptions. Share is of FY26 revenue by customer location (₹8,161 crore); the India business unit reported ₹7,645 crore.
  • Customers in the US · 9.7% of revenueBuyers of Torrent's generic medicines in the US: ₹1,363 crore in FY26, against ₹1,100 crore in FY25.
  • Customers in Brazil · 9.7% of revenueBuyers of Torrent's branded generics in Brazil: ₹1,362 crore in FY26.
  • Customers in Germany and Malta · 8.9% of revenueBuyers of Torrent's generic medicines in Germany, including through tenders: ₹1,249 crore in FY26.
  • Customers in other countries · 13.2% of revenueBuyers in more than 50 markets in all, and companies that pay for contract manufacturing: ₹1,845 crore in FY26.

Sources: Sun Pharma S1, S27, S18 · Torrent Pharma S1, S8

Revenue by segment

Sun Pharma

FY26

Sun Pharma revenue by segment, FY26
SegmentRevenueShare
India₹19,694 cr33.8%
United States₹17,620 cr30.3%
Emerging markets₹11,684 cr20.1%
Rest of the world₹9,222 cr15.8%

Torrent Pharma

FY26

Torrent Pharma revenue by segment, FY26
SegmentRevenueShare
India₹7,645 cr54.7%
Brazil₹1,362 cr9.7%
USA₹1,363 cr9.7%
Germany₹1,249 cr8.9%
Others₹2,361 cr16.9%

Sources: Sun Pharma S1 · Torrent Pharma S1, S47, S2, S38

Borrowings and cash

Sun Pharma

Borrowings
₹2,694 cr
Cash and investments
₹33,570 cr

On 30 Sep 2026.

On 30 Sep 2026 Sun Pharma's cash and liquid investments were ₹30,877 crore more than its borrowings, before it raised ₹7,816 crore through bonds in Oct 2026.

Torrent Pharma

Borrowings
₹13,874 cr
Cash and investments
₹2,986 cr

On 30 Sep 2026.

On 30 Sep 2026 Torrent's borrowings were ₹10,888 crore more than its cash and liquid investments, down from ₹12,767 crore on 31 Mar 2026 (Cityfort calculation from the results); the company put net debt at 1.8 times EBITDA.

Sources: Sun Pharma S9, S1, S56, S40, S11, S44 · Torrent Pharma S7, S6, S12, S20, S1, S9, S11, S13, S38

Who owns each company

Sun Pharma

  • Promoters: 52.7%
  • Foreign institutional investors (FIIs): 14.4%
  • Indian institutions (DIIs): 22.3%
  • Public: 10.7%
  • Pledged: 0.0% of the promoter holding.
  • Shareholding pattern at the end of Q2 FY27.

Torrent Pharma

  • Promoters: 60.8%
  • Foreign institutional investors (FIIs): 17.2%
  • Indian institutions (DIIs): 13.5%
  • Public: 8.5%
  • Pledged: 0.0% of the promoter holding.
  • Shareholding pattern at the end of Q2 FY27.

Sources: Sun Pharma S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S38, S39, S46, S47 · Torrent Pharma S25, S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S42

What protects each business

What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.

Sun Pharma

  • Size in India

    ₹21,538 crore of India medicine sales and an 8.5% share in the 12 months to Jun 2026 (AIOCD), against 5.9% for the next name in the same list (Abbott, Abbott Healthcare and Novo combined).

  • Reach to doctors

    Over 16,000 field staff on 30 Jun 2026. Sun Pharma says it ranks first by prescriptions among 12 groups of doctors (SMSRC data).

  • Brands

    30 of India's top 300 medicine brands (AIOCD, Jun 2026). Its top 10 brands were about 17% of India revenue, so sales are spread across many brands.

  • Product approvals

    561 approved US generic applications and 58 approved new-drug applications on 30 Sep 2026, with 120 and 12 more pending.

  • Cash on hand

    On 30 Sep 2026 cash and liquid investments of ₹33,570 crore exceeded borrowings of ₹2,694 crore. CRISIL rated Sun Pharma AAA/Stable on 13 Oct 2026.

Torrent Pharma

  • Heart and long-term medicines in India

    The FY26 annual report ranks Torrent 1st in India's heart (cardiac) medicines, 3rd in brain and nerve (CNS) and stomach (GI) medicines, and 4th in chronic and sub-chronic medicines.

  • Repeat prescriptions

    ICRA says chronic and sub-chronic medicines, taken for months or years, were about 76% of Torrent's FY25 India revenue.

  • Sales force

    9,100 people calling on doctors in India at the end of Q2 FY27, Torrent and JB combined.

  • Spread across markets

    By the annual report's business-unit figures, India gave 54.7% of FY26 revenue, and Brazil, the US and Germany 8.9% to 9.7% each; Torrent sells in more than 50 markets.

Sources: Sun Pharma S27, S10, S9, S40 · Torrent Pharma S1, S49, S39, S9

Where growth could come from

Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.

Sun Pharma

  • Branded medicines in India · Working: on track against what the company saidIndia sales +17.3%, Q2 FY27
  • Innovative medicines · Working: on track against what the company saidUS$1,420 million, FY26 (+16.4% excluding a milestone payment)
  • US generics · Mixed: partly on trackUS$455 million, Q2 FY27 (−8.2%)
  • Organon purchase · Early: too early to judgeEnterprise value US$11.75 billion; not closed
  • New plant in Madhya Pradesh · New: recently announced₹3,000 crore, approved 2 Dec 2025

Torrent Pharma

  • Torrent's own India business · Working: on track against what the company said₹2,181 crore, Q2 FY27 (+20%)
  • JB Pharma · Mixed: partly on track₹1,086 crore, Q2 FY27 (largely flat)
  • Brazil · Working: on track against what the company said+38% in rupees, Q2 FY27
  • US generics · Working: on track against what the company saidUS$44 million, Q2 FY27 (+13% in constant currency)
  • Germany · Behind: behind the company's own plan€26 million, Q2 FY27 (−13% in constant currency)
  • Semaglutide in India · Mixed: partly on track32% market share, Q2 FY27 (36% in Q1)

Sources: Sun Pharma S10, S18, S12, S11, S45, S50 · Torrent Pharma S8, S9, S49, S11

Dividends, buybacks, auditor and credit rating

Dividends per share and buybacks for up to five years, the statutory auditor and the latest credit rating, as each page records them.

Sun Pharma

  • Dividends per shareFY22: ₹10.00 (73.5% of profit) · FY23: ₹11.50 (32.6% of profit) · FY24: ₹13.50 (33.8% of profit) · FY25: ₹16.00 (35.1% of profit) · FY26: ₹16.00 (33.5% of profit)
  • BuybacksNone on the page in the last five years.
  • AuditorS R B C & Co LLP
  • Credit ratingCRISIL: AAA (long term), A1+ (short term), outlook Stable (13 Oct 2026)

Torrent Pharma

  • Dividends per shareFY22: ₹24.00 (104.5% of profit) · FY23: ₹22.00 (59.8% of profit) · FY24: ₹28.00 (57.2% of profit) · FY25: ₹32.00 (56.7% of profit) · FY26: ₹38.00 (59.4% of profit)
  • BuybacksNone on the page in the last five years.
  • AuditorB S R & Co. LLP
  • Credit ratingIndia Ratings and Research: IND AA+ (long term) affirmed; IND A1+ (commercial paper), outlook Positive (revised from Stable) (7 Oct 2026)

Sources: Sun Pharma S3, S7, S6, S5, S1, S40 · Torrent Pharma S5, S4, S3, S2, S1, S40

Risks only one page tracks

Risks whose type the other company's page does not list. Both pages track risks of these types: regulation, debt, competition. Every risk is on each company's page.

Sun Pharma

  • US lawsuits and settlements (legal cases)One-off charges for US legal settlements recur: ₹3,723 crore in FY22, US$200 million in FY26 and ₹923 crore in Q2 FY27, all settled without admitting wrongdoing. In Aug 2026 a US appeals court ruled for Sun Pharma in the Lipitor antitrust case.
  • Small promoter pledge (governance)On 30 Sep 2026, 85,000 promoter-group shares held by Kumud Shantilal Shanghvi were pledged, 0.01% of the promoter holding. Pledged shares are given as loan collateral; a lender can sell them if a loan is not repaid.

Torrent Pharma

  • Joining JB into Torrent (execution)JB's revenue was largely flat at ₹1,086 crore in Q2 FY27 and its international business fell 7%. The company said merging sales teams, plants and quality systems had a "transient impact" and postponed some deliveries.
  • Amortisation and goodwill (other)Depreciation and amortisation was ₹609 crore in Q2 FY27, against ₹204 crore in Q2 FY26. On 30 Sep 2026 goodwill (₹3,990 crore) and other intangible assets (₹23,352 crore) together exceeded net worth of ₹18,373 crore.
  • Relying on a partner for semaglutide injections (customer or supplier concentration)A manufacturing partner's supply problem kept Torrent's semaglutide injections off the market for nearly two months in 2026; a new partner restored supply by Sep 2026. Combined market share went from 36% in Q1 FY27 to 32% in Q2 FY27.
  • Currency swings (currency)About 41% of FY26 revenue came from exports (BRSR). Other income, which nets foreign-exchange gains and losses, was negative in every quarter from Q4 FY25 to Q2 FY27 and −₹94 crore for FY26.

Sources: Sun Pharma S7, S9, S53, S55, S39, S38 · Torrent Pharma S8, S9, S49, S7, S17, S11, S1, S6

Key facts

How does Sun Pharma make money compared with Torrent Pharma?
Sun Pharma's revenue by segment in FY26: India 33.8%, United States 30.3%, Emerging markets 20.1%, Rest of the world 15.8%. Torrent Pharma's revenue by segment in FY26: India 54.7%, Brazil 9.7%, USA 9.7%, Germany 8.9%, Others 16.9%.
Which is bigger by revenue, Sun Pharma or Torrent Pharma?
Sun Pharma reported revenue of ₹58,462 cr in FY26, and Torrent Pharma reported revenue of ₹13,980 cr in FY26.
How much net profit did Sun Pharma and Torrent Pharma report?
Sun Pharma reported a net profit of ₹11,479 cr in FY26, and Torrent Pharma reported ₹2,163 cr in FY26.
How much of every ₹100 did Sun Pharma and Torrent Pharma keep as profit?
Sun Pharma kept ₹19.0 of every ₹100 that came in during FY26, and Torrent Pharma kept ₹15.6 in FY26 (Cityfort calculation from each company's annual report).
How much do Sun Pharma and Torrent Pharma owe, and how much cash do they hold?
Sun Pharma had borrowings of ₹2,694 cr and cash and investments of ₹33,570 cr on 30 Sep 2026. Torrent Pharma had borrowings of ₹13,874 cr and cash and investments of ₹2,986 cr on 30 Sep 2026.
Who owns Sun Pharma and Torrent Pharma?
Promoters held 52.7% of Sun Pharma's shares at the end of Q2 FY27, and 0.0% of the promoter holding was pledged. Promoters held 60.8% of Torrent Pharma's shares at the end of Q2 FY27, with none of it pledged. Both come from the shareholding patterns the companies filed with NSE and BSE.
When do Sun Pharma's and Torrent Pharma's financial years end?
Sun Pharma and Torrent Pharma both use the Indian financial year, April to March. The latest full year is FY26 on the Sun Pharma page and FY26 on the Torrent Pharma page.

Sources: Sun Pharma S7, S6, S5, S1, S27, S18, S9, S56, S40, S11, S44 · Torrent Pharma S24, S5, S4, S23, S22, S3, S20, S2, S12, S1, S47, S38, S8, S7, S6, S9, S11, S13

Built from each company's page. Sun Pharma updated 11 Nov 2026; Torrent Pharma updated 12 Nov 2026.

Sources

Sun Pharma

  1. S1Annual Report FY26: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 6 Jul 2026
  2. S3Annual Report FY26: Board's Report and Corporate Governance section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 6 Jul 2026
  3. S5Annual Report FY25: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 4 Jul 2025
  4. S6Annual Report FY24: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 8 Jul 2024
  5. S7Annual Report FY23: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 27 Jul 2023
  6. S9Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
  7. S10Press release: Sun Pharma reports Q2FY27 results, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
  8. S11Q2 FY27 earnings presentation, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
  9. S12Q2 FY27 earnings call transcript (call 30 Oct 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 4 Nov 2026
  10. S13Unaudited consolidated financial results Q1 FY27 (quarter ended 30 Jun 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 31 Jul 2026
  11. S17Audited consolidated financial results Q4 FY26 and FY26, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 May 2026
  12. S18Press release: Sun Pharma reports Q4FY26 and FY26 results, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 May 2026
  13. S20Unaudited consolidated financial results Q3 FY26 (quarter ended 31 Dec 2025), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 31 Jan 2026
  14. S27Investor presentation, September 2026 ("Creating Lasting Value"), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 Sep 2026
  15. S28Shareholding pattern as of 31 Dec 2023 (NSE XBRL), NSE (company filing), 16 Jan 2024
  16. S29Shareholding pattern as of 31 Mar 2024 (NSE XBRL), NSE (company filing), 18 Apr 2024
  17. S30Shareholding pattern as of 30 Jun 2024 (NSE XBRL), NSE (company filing), 19 Jul 2024
  18. S31Shareholding pattern as of 30 Sep 2024 (NSE XBRL), NSE (company filing), 16 Oct 2024
  19. S32Shareholding pattern as of 31 Dec 2024 (NSE XBRL), NSE (company filing), 20 Jan 2025
  20. S33Shareholding pattern as of 31 Mar 2025 (NSE XBRL), NSE (company filing), 17 Apr 2025
  21. S34Shareholding pattern as of 30 Jun 2025 (NSE XBRL), NSE (company filing), 21 Jul 2025
  22. S35Shareholding pattern as of 30 Sep 2025 (NSE XBRL), NSE (company filing), 16 Oct 2025
  23. S36Shareholding pattern as of 31 Dec 2025 (NSE XBRL), NSE (company filing), 15 Jan 2026
  24. S37Shareholding pattern as of 31 Mar 2026 (NSE XBRL, revised filing), NSE (company filing), 17 Jun 2026
  25. S38Shareholding pattern as of 30 Jun 2026 (NSE XBRL), NSE (company filing), 17 Jul 2026
  26. S39Shareholding pattern as of 30 Sep 2026 (NSE XBRL), NSE (company filing), 15 Oct 2026
  27. S40Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 13 Oct 2026
  28. S44Intimation: international credit ratings (Moody's Baa1, S&P BBB+), Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 8 Sep 2026
  29. S45Intimation and press release: definitive agreement to acquire Organon & Co., Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 27 Apr 2026
  30. S46Intimation: receipt of requests for reclassification from promoter group to public (Valia family), Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 14 May 2026
  31. S47Intimation: shareholders approve reclassification from promoter group to public, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 26 Sep 2026
  32. S50Intimation: approval of ₹3,000 crore greenfield formulations facility in Madhya Pradesh, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 2 Dec 2025
  33. S53Intimation: settlement agreement with a plaintiff in the generic drug pricing antitrust litigation (US), Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 11 Sep 2026
  34. S55Intimation: update on Lipitor antitrust litigation (US appeals court affirms judgment for the company), Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 17 Aug 2026
  35. S56Intimation: allotment of non-convertible debentures of ₹7,816 crore, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 26 Oct 2026

Torrent Pharma

  1. S1Integrated Annual Report 2025-26 (FY26), Torrent Pharmaceuticals Ltd (company IR site), 1 Jun 2026
  2. S2Annual Report 2024-25 (FY25), Torrent Pharmaceuticals Ltd (company IR site), 4 Jul 2025
  3. S3Annual Report 2023-24 (FY24), Torrent Pharmaceuticals Ltd (company IR site), 29 Jun 2024
  4. S4Annual Report 2022-23 (FY23), Torrent Pharmaceuticals Ltd (company IR site), 14 Jul 2023
  5. S5Annual Report 2021-22 (FY22), Torrent Pharmaceuticals Ltd (company IR site), 4 Jul 2022
  6. S6Consolidated financial results, quarter and half year ended 30 Sep 2026 (Q2 FY27), Torrent Pharmaceuticals Ltd (company IR site), 23 Oct 2026
  7. S7Integrated filing (financials) XBRL, consolidated, Q2 FY27, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 23 Oct 2026
  8. S8Press release: Torrent Pharma announces Q2 FY27 results, Torrent Pharmaceuticals Ltd (company IR site), 23 Oct 2026
  9. S9Q2 FY27 earnings call transcript (call 23 Oct 2026), Torrent Pharmaceuticals Ltd (company IR site), 29 Oct 2026
  10. S10Integrated filing (financials) XBRL, consolidated, Q1 FY27, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 30 Jul 2026
  11. S11Q1 FY27 earnings call transcript (call 30 Jul 2026), Torrent Pharmaceuticals Ltd (company IR site), 4 Aug 2026
  12. S12Integrated filing (financials) XBRL, consolidated, Q4 FY26 and FY26, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 22 May 2026
  13. S13Q4 FY26 earnings call transcript (call 22 May 2026), Torrent Pharmaceuticals Ltd (company IR site), 26 May 2026
  14. S14Integrated filing (financials) XBRL, consolidated, Q3 FY26, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 13 Feb 2026
  15. S17Integrated filing (financials) XBRL, consolidated, Q2 FY26, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 7 Nov 2025
  16. S20Integrated filing (financials) XBRL, consolidated, Q4 FY25 and FY25, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 20 May 2025
  17. S22Financial results XBRL, consolidated, Q4 FY24 and FY24, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 24 May 2024
  18. S23Financial results XBRL, consolidated, Q4 FY23 and FY23, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 30 May 2023
  19. S24Financial results XBRL, consolidated, Q4 FY22 and FY22, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 25 May 2022
  20. S25Shareholding pattern as of 31 Dec 2023, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 12 Jan 2024
  21. S26Shareholding pattern as of 31 Mar 2024, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 19 Apr 2024
  22. S27Shareholding pattern as of 30 Jun 2024, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 12 Jul 2024
  23. S28Shareholding pattern as of 30 Sep 2024, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 11 Oct 2024
  24. S29Shareholding pattern as of 31 Dec 2024, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 16 Jan 2025
  25. S30Shareholding pattern as of 31 Mar 2025, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 18 Apr 2025
  26. S31Shareholding pattern as of 30 Jun 2025, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 19 Jul 2025
  27. S32Shareholding pattern as of 30 Sep 2025, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 13 Oct 2025
  28. S33Shareholding pattern as of 31 Dec 2025, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 3 Jan 2026
  29. S34Shareholding pattern as of 31 Mar 2026, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 17 Apr 2026
  30. S35Shareholding pattern as of 30 Jun 2026, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 20 Jul 2026
  31. S36Shareholding pattern as of 20 Jul 2026 (capital change after JB merger allotment), National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 20 Jul 2026
  32. S37Shareholding pattern as of 30 Sep 2026, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 15 Oct 2026
  33. S38ICRA rationale: Torrent Pharmaceuticals Limited, change in limits (21 Jul 2026), ICRA Limited, 21 Jul 2026
  34. S39ICRA rationale: ratings reaffirmed; [ICRA]A1+ assigned for fresh CPs (5 Jan 2026, revised), ICRA Limited, 5 Jan 2026
  35. S40Intimation of credit rating: India Ratings affirms IND AA+, outlook revised to Positive, National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 7 Oct 2026
  36. S42SAST Reg 29(2) disclosure: Torrent Investments sold 9,944,040 shares (2.94%) on 30 Oct 2024, National Stock Exchange of India (filed by Torrent Investments), 30 Oct 2024
  37. S47Investor presentation: audited results for Q4 FY26 and FY26 (filed with NSE), National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 22 May 2026
  38. S49Press release: Torrent Pharma announces Q1 FY27 results (with results filing), National Stock Exchange of India (filed by Torrent Pharmaceuticals Ltd), 30 Jul 2026

Disclaimer

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.

Read the full disclaimer

Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.

All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management are reported as statements, with their date and source; they are not our forecasts.